Arzneimittel mit dem Wirkstoff Naproxen (ATC: M01AE02)

TENDER DESCRIPTION

Conclusion of non-exclusive rebate agreements according to § 130a para. 8 SGB V for finished medicinal products containing the active ingredient Naproxen (ATC: M01AE02) with the possibility to conclude at any time within the framework of a so-called "open-house model". A contract is concluded with every pharmaceutical company that meets the participation requirements. Exclusivity is not granted. Accession or contract conclusion can take place at any time and under the same conditions. Individual contract negotiations are not conducted. The earliest contract start date is 01.10.2026. Based on this, the contract duration is a maximum of 24 months. The contract ends on 30.09.2028 regardless of the start date of the contract. Should AOK Sachsen-Anhalt tender exclusive contracts for the active ingredients during the contract period in accordance with the relevant procurement law provisions, the contracts concluded under this publication will be terminated according to the contractual provisions. This publication does not constitute the awarding of a public contract within the meaning of § 103 GWB or procurement law. To ensure the highest possible level of transparency for the intended…

TENDER BRIEF

TENDER DOCUMENTS